Scarica l'app Stockscreener
122.16
3.51%
6.16
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$116.00
Aprire:
$117.5
Volume 24 ore:
2.92M
Relative Volume:
1.10
Capitalizzazione di mercato:
$26.43B
Reddito:
$819.56M
Utile/perdita netta:
$-1.18B
Rapporto P/E:
-21.27
EPS:
-5.7434
Flusso di cassa netto:
$-951.64M
1 W Prestazione:
-12.41%
1M Prestazione:
-20.55%
6M Prestazione:
-37.12%
1 anno Prestazione:
+82.73%
Intervallo 1D:
$112.00
$122.08
Intervallo di 1 settimana:
$98.90
$125.36
Portata 52W:
$64.84
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
121.95 | 25.14B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
451.36 | 113.78B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
715.68 | 75.84B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.37 | 50.55B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.12 | 38.99B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
313.47 | 32.69B | 5.76B | 514.49M | 1.10B | 4.4813 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2026-03-30 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-12-19 | Ripresa | Truist | Buy |
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Where Could The Next Breakout for Insmed Stock Come From - Trefis
Insmed (INSM) Soars on Bargain-Hunting After 10-Month Low - Yahoo Finance
Insmed's Q1 earnings beat, sales miss estimates, stock tanks 23% - MSN
Insmed Stock Drops As Analysts Call Post-Earnings Selloff Overdone - StocksToTrade
INSM Stock Slides As Analysts Call Post-Earnings Selloff Overdone - timothysykes.com
Insmed Stock Dips As Analysts Double Down On Bullish Targets - StocksToTrade
BofA reiterates Insmed stock buy rating on strong Brinsupri launch By Investing.com - Investing.com Canada
BofA reiterates Insmed stock buy rating on strong Brinsupri launch - Investing.com India
Insmed shares jump as investors refocus on guidance and conference presentation - Quiver Quantitative
[144] INSMED Inc SEC Filing - Stock Titan
INSM Stock Quote Price and Forecast - CNN
Barclays Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $237 - Moomoo
Zoetis, Insmed, and HubSpot are among top 10 large-cap losers last week (May 4-May 8): Are the others in your portfolio? - MSN
INSM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $160 to $237 - Moomoo
Insmed Incorporated (NASDAQ:INSM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Moomoo
Here's What Analysts Are Forecasting For Insmed Incorporated (NASDAQ:INSM) After Its First-Quarter Results - Yahoo Finance
Insmed (INSM) Q1 2026 Revenue Surge Tests Profitability Narrative - simplywall.st
Insmed (INSM) Post-Earnings Selloff Seen as Buying Opportunity - GuruFocus
INSM Maintained by RBC Capital -- Price Target Lowered to $205 - GuruFocus
INSM Maintained by Wells Fargo -- Price Target Lowered to $160 - GuruFocus
Insmed Stock Sell-off Is Overdone as Underlying Metrics Appear Positive, RBC Says - Moomoo
RBC Cuts Price Target on Insmed to $205 From $220, Keeps Outperform Rating - Moomoo
Insmed Stock Sell-off is Overdone as Underlying Metrics Appear Positive, RBC Says - marketscreener.com
INSM Maintains by Guggenheim -- Price Target Lowered to $226 - GuruFocus
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $160 to $243 - Moomoo
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23% - TradingView
Insmed’s 44% decline validates InvestingPro’s overvalued call By Investing.com - Investing.com
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
Insmed Q1 2026 slides: BRINSUPRI surges 44%, ARIKAYCE expansion ahead By Investing.com - Investing.com South Africa
Insmed Q1 Earnings Call Highlights - Yahoo Finance
TD Cowen Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $243 - Moomoo
Insmed Earnings Call Highlights BRINSUPRI-Driven Momentum - TipRanks
Insmed's Blockbuster Drug Brinsupri Drives Record Revenue, Yet Shares Tumble - AD HOC NEWS
Insmed (INSM) Q1 2026 Earnings Transcript - The Globe and Mail
Roth MKM Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $212 - Moomoo
Insmed Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance
Insmed Bronchiectasis Push With Ty Pennington May Expand Therapy Opportunity - simplywall.st
U.S. Indexes Closed Down Thursday; Insmed Fell Furthest - Barron's
Insmed reiterates BRINSUPRI at least $1B 2026 revenue target while targeting ARIKAYCE label expansion in H1 2027 - MSN
Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish - Investor's Business Daily
Insmed Down Over 21%, Worst Performer in the Nasdaq 100 So Far Today -- Data Talk - Moomoo
Insmed Q1 2026 slides: BRINSUPRI surges 44%, ARIKAYCE expansion ahead - Investing.com
Earnings call transcript: Insmed Q1 2026 beats forecasts but stock tumbles - Investing.com
Nasdaq 100 Climbs Records, Oil Extends Drop As Iran Weighs Hormuz Deal: Stock Market Today - Benzinga
Earnings call transcript: Insmed Q1 2026 beats forecasts but stock tumbles By Investing.com - Investing.com South Africa
William Blair Maintains Insmed(INSM.US) With Buy Rating - Moomoo
IBD: Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish - Moomoo
INSM: BRINSUPRI's launch outperformed expectations, driving strong revenue and sustained growth - TradingView
Why is Insmed stock sliding today? - Investing.com
Why is Insmed stock sliding today? By Investing.com - Investing.com Canada
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insmed Inc Azioni (INSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
May 04 '26 |
Option Exercise |
24.94 |
10,699 |
266,840 |
311,884 |
| Lewis William | Chair and CEO |
May 04 '26 |
Sale |
137.34 |
10,699 |
1,469,442 |
301,185 |
0.80%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):